AVEO Pharmaceuticals, Inc. to Present at Several Upcoming Investment Conferences
CAMBRIDGE, Mass., Feb 23, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) today announced that members of the company's management team are scheduled to present a corporate overview at several upcoming investment conferences. The conference and AVEO presentation details are as follows:
- RBC Capital Markets' 2011 Healthcare Conference on Wednesday, March 2, 2011 at 3:35 p.m. (ET) at the New York Palace Hotel in New York City.
- Citi 2011 Global Health Care Conference on Thursday, March 3, 2011 at 9:00 a.m. (ET) at the Hilton New York Hotel in New York City.
- Cowen and Company 31st Annual Health Care Conference on Monday, March 7, 2011 at 3:15 p.m. (ET) at the Boston Marriott Copley Place in Boston.
- Barclays Capital 2011 Global Healthcare Conference on Wednesday, March 16, 2011 at 4:45 p.m. (ET) at the Loews Miami Hotel in Miami.
Webcasts of AVEO's presentations can be accessed by visiting the investors section of the company's website at investor.aveopharma.com. A replay of the webcasts will be archived on the AVEO website for two weeks following each presentation date, respectively.
AVEO Pharmaceuticals (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patients' lives. The company's lead product candidate, tivozanib, is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in patients with advanced renal cell carcinoma, as well as additional clinical studies in other solid tumor types. AVEO's second most advanced product candidate, ficlatuzumab (AV-299), is a potent, functional anti-HGF/c-MET pathway antibody that is currently in Phase 2 clinical development. AVEO's proprietary Human Response Platform(TM) is designed to offer the company a unique advantage in cancer drug development and has provided a discovery engine for multiple therapeutic targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information, please visit the company's website at www.aveopharma.com.
SOURCE: AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc.
Monique Allaire, 617-299-5810
Caton Lovett, 910-232-7166